LOGIN
Strontium ranelate and alfa D3 improve outcomes of postmenopausal osteoporosis
March 2015
Strontium ranelate and alfa D3 improve outcomes of postmenopausal osteoporosis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Efficacy of Strontium Ranelate in Combination with a D-Hormone Analog for the Treatment of Postmenopausal Osteoporosis
Drugs R D. 2014 Dec;14(4):315-24.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
48 women with postmenopausal osteoporosis were randomized to either a group which received a combination of strontium ranelate (SrRan) and alfacalcidol (alfa D3), a group which received SrRan, or a control group. All groups also received calcium and vitamin D3 supplementation. The purpose of this study was to compare the efficacy of SrRan in combination with alfa D3, and SrRan alone on bone minera...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.